AbstractFew studies have linked sensory descriptions of the aroma profiles of fresh, sweet basil varieties with their volatile chemistry. Using a recently developed lexicon for fresh basil, a descriptive panel characterized the aroma profiles of seven basil varieties. Chemical analysis of fresh basil leaves was performed using GC‐MS headspace analysis. Analysis of variance probed for differences in the sensory attributes among varieties and principal component analysis (PCA) related the sensory profiles to volatile chemical composition. Three commercial specialty basils, “Queenette Thai” (QT), “Sweet‐Dani” (SD) lemon basil, and MC‐9 (cinnamon basil) had strong anise, lemon, and cinnamon‐like aromas, respectively. These basils were distinguished from breeding lines of traditional Italian sweet basils where SB‐22, CB‐1, and CB‐39 exhibited strong anise‐like aroma and SB‐17 had strong “general spice” aromas, characteristic of a warm spice blend. The PCA accounted for 58.7% of the variation in the data and characterized the samples in two dimensions: general spice—citrus and cinnamon‐like—anise. There was a strong correspondence between the sensory attributes and volatile chemical composition. SD associated with lemon aroma and citral content; QT, CB‐1, and CB‐39 associated with anise aroma and methyl chavicol; and MC‐9 associated with the cinnamon‐like aroma, methyl cinnamate. SB‐17 and SB‐22 associated with general spice aroma and were in close proximity to the spice‐like volatiles, 1,8 cineole, and eugenol, associated with clove aroma. We constructed precise sensory/chemical profiles for fresh basil aroma that can be used to guide breeding programs for variety improvement to meet consumer expectations or market demand.Practical ApplicationSweet basil aroma is due to a complex array of several aromatic volatile compounds. The presence, concentration, and the particular ratios in which these aroma compounds accumulate significantly impact the sensory attributes. Understanding aroma profiles for fresh basil have practical applications in product development, procurement, food preparation, ethnic cuisine, and processing. Plant genetics and breeding of aroma profiles can be used and incorporated in plant improvement programs.

01 Sep 2012·Pediatric TransplantationQ4 · MEDICINE

Liver transplantation for a pediatric patient with hemophilia B

Q4 · MEDICINE

Article

Author: Koichi Mizuta ; Yoshiyuki Ihara ; Naoya Yamada ; Taiichi Wakiya ; Noriki Okada ; Taizen Urahashi ; Yukihiro Sanada

Sanada Y, Urahashi T, Ihara Y, Wakiya T, Okada N, Yamada N, Mizuta K. Liver transplantation for a pediatric patient with hemophilia B.  Pediatr Transplantation 2012: 00: 000–000. © 2012 John Wiley & Sons A/S.Abstract: Hemophilia exposes patients to greater risks of bleeding complications during the perioperative period. However, there are no current protocols for factor replacement during LT. We herein describe a case of pediatric living donor LDLT performed for a patient with hemophilia B using perioperative short‐term factor replacement. A 4‐yr‐old female patient with an extrahepatic portosystemic shunt and asymptomatic hemophilia B (factor IX activity 18.7%) underwent an ABO‐compatible LDLT using a left lobe graft. The bleeding volume was 2980 mL. Freeze‐dried human blood coagulation factor IX concentrate (Novact M, Kaketsuken, Japan) was administered at the induction of anesthesia and at the end of LDLT by bolus infusion (80 U/kg) and was continued by bolus infusion (40 U/kg) on POD 1, 2, 3, and 4. On POD 1, 5, 8, and 12, the factor IX plasma levels were 34.5%, 64.9%, 43.5%, and 53.1%, respectively. The postoperative course was uneventful, and the patient is currently doing well at 2.5 yr after LDLT. Factor concentrate should be administered at the induction of anesthesia and at the end of LT by bolus infusion, and thereafter be continued for a few days after LT by bolus infusion.

18 Jun 2008·Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[Preparation and characterization of monoclonal antibodies against CMTM7].

Article

Author: Chen, Ying Yu ; Zhang, Ting ; Shao, Lu Ning ; Han, Wen Ling ; Xu, Lan Jun ; Song, Quan Sheng

OBJECTIVETo obtain monoclonal antibodies against CMTM7 (CKLF-like MARVEL transmembrane domain containing 7) for further study of the structure and biological function of CMTM7.METHODSThree polypeptides were synthesized based on the bioinformatics analysis of the CMTM7 and coupled with keyhole limpet hemocyanin (KLH). Balb/c mice were immunized with these mixed CMTM7 polypeptides. Hybridomas were generated by the fusion of the spleenocytes from these mice with Sp2/0 myeloma cells. Resulting hybridomas producing anti-CMTM7 antibodies were screened by enzymejlinked immunosorbent assay (ELISA). The specificities of these monoclonal antibodies were determined by Western blot, immunofluorescecence and immunocytochemistry (ICC).RESULTSTwo hybridoma cell lines (MC9 and 2C9) stable in secreting anti-CMTM7 monoclonal antibodies (MAbs) were generated. Both of them produced immunoglobulin G1 (IgG1) against CMTM7. 2C9 and MC9 recognized a region between amino acid residues 19-44 and 163-175 of CMTM7, respectively. MC9 antibody could be used for Western blot, immunofluorescecence and immunocytochmistry assay. However, 2C9 antibody could be only used for Western blot. Data obtained from immunofluorescence and ICC indicated that CMTM7 protein expression was upregulated in the early stage of lymphocyte activation treated with phytohemagglutinin (PHA).CONCLUSIONMonoclonal antibodies of high specificity against CMTM7 have been successfully generated, which could be utilized as a useful reagent for the analysis of biochemical, structural, and functional properties of CMTM7.

100 Deals associated with Human Blood Coagulation Factor IX(KM Biologics KK)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hemophilia B	Hungary	Octapharma GmbH	02 Jan 2002
Hemophilia B	Malta	Octapharma GmbH	02 Jan 2002
Hemophilia B	Finland	Octapharma GmbH	02 Jan 2002
Hemophilia B	Denmark	Octapharma GmbH	02 Jan 2002
Hemophilia B	Slovenia	Octapharma GmbH	02 Jan 2002
Hemophilia B	Latvia	Octapharma GmbH	02 Jan 2002
Hemophilia B	Spain	Octapharma GmbH	02 Jan 2002
Hemophilia B	Lithuania	Octapharma GmbH	02 Jan 2002
Hemophilia B	Poland	Octapharma GmbH	02 Jan 2002
Hemophilia B	Slovakia	Octapharma GmbH	02 Jan 2002
Hemophilia B	Romania	Octapharma GmbH	02 Jan 2002
Hemophilia B	Luxembourg	Octapharma GmbH	02 Jan 2002
Hemophilia B	Sweden	Octapharma GmbH	02 Jan 2002
Hemophilia B	Germany	Octapharma GmbH	02 Jan 2002
Hemophilia B	Bulgaria	Octapharma GmbH	02 Jan 2002
Hemophilia B	Cyprus	Octapharma GmbH	02 Jan 2002
Hemophilia B	Norway	Octapharma GmbH	02 Jan 2002
Hemophilia B	France	Octapharma GmbH	02 Jan 2002
Hemophilia B	Estonia	Octapharma GmbH	02 Jan 2002
Hemorrhage	Japan	KM Biologics KK	04 Oct 1991

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Human Blood Coagulation Factor IX(KM Biologics KK)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation